Engineering enhanced CAR T-cells for improved cancer therapy

Chimeric antigen receptor (CAR) T-cell therapies have evolved from a research tool to a paradigm-shifting therapy with impressive responses in B cell malignancies. This review summarizes the current state of the CAR T-cell field, focusing on CD19- and B cell maturation antigen-directed CAR T-cells,...

Descripción completa

Detalles Bibliográficos
Autores principales: Milone, Michael C., Xu, Jie, Chen, Sai-Juan, Collins, McKensie A., Zhou, Jiafeng, Powell, Daniel J., Melenhorst, J. Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8412433/
https://www.ncbi.nlm.nih.gov/pubmed/34485921
http://dx.doi.org/10.1038/s43018-021-00241-5
_version_ 1783747453159211008
author Milone, Michael C.
Xu, Jie
Chen, Sai-Juan
Collins, McKensie A.
Zhou, Jiafeng
Powell, Daniel J.
Melenhorst, J. Joseph
author_facet Milone, Michael C.
Xu, Jie
Chen, Sai-Juan
Collins, McKensie A.
Zhou, Jiafeng
Powell, Daniel J.
Melenhorst, J. Joseph
author_sort Milone, Michael C.
collection PubMed
description Chimeric antigen receptor (CAR) T-cell therapies have evolved from a research tool to a paradigm-shifting therapy with impressive responses in B cell malignancies. This review summarizes the current state of the CAR T-cell field, focusing on CD19- and B cell maturation antigen-directed CAR T-cells, the most developed of the CAR T-cell therapies. We discuss the many challenges to CAR-T therapeutic success and innovations in CAR design and T-cell engineering aimed at extending this therapeutic platform beyond hematologic malignancies.
format Online
Article
Text
id pubmed-8412433
institution National Center for Biotechnology Information
language English
publishDate 2021
record_format MEDLINE/PubMed
spelling pubmed-84124332022-02-01 Engineering enhanced CAR T-cells for improved cancer therapy Milone, Michael C. Xu, Jie Chen, Sai-Juan Collins, McKensie A. Zhou, Jiafeng Powell, Daniel J. Melenhorst, J. Joseph Nat Cancer Article Chimeric antigen receptor (CAR) T-cell therapies have evolved from a research tool to a paradigm-shifting therapy with impressive responses in B cell malignancies. This review summarizes the current state of the CAR T-cell field, focusing on CD19- and B cell maturation antigen-directed CAR T-cells, the most developed of the CAR T-cell therapies. We discuss the many challenges to CAR-T therapeutic success and innovations in CAR design and T-cell engineering aimed at extending this therapeutic platform beyond hematologic malignancies. 2021-08-19 2021-08 /pmc/articles/PMC8412433/ /pubmed/34485921 http://dx.doi.org/10.1038/s43018-021-00241-5 Text en https://www.springernature.com/gp/open-research/policies/accepted-manuscript-termsUsers may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: https://www.springernature.com/gp/open-research/policies/accepted-manuscript-terms
spellingShingle Article
Milone, Michael C.
Xu, Jie
Chen, Sai-Juan
Collins, McKensie A.
Zhou, Jiafeng
Powell, Daniel J.
Melenhorst, J. Joseph
Engineering enhanced CAR T-cells for improved cancer therapy
title Engineering enhanced CAR T-cells for improved cancer therapy
title_full Engineering enhanced CAR T-cells for improved cancer therapy
title_fullStr Engineering enhanced CAR T-cells for improved cancer therapy
title_full_unstemmed Engineering enhanced CAR T-cells for improved cancer therapy
title_short Engineering enhanced CAR T-cells for improved cancer therapy
title_sort engineering enhanced car t-cells for improved cancer therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8412433/
https://www.ncbi.nlm.nih.gov/pubmed/34485921
http://dx.doi.org/10.1038/s43018-021-00241-5
work_keys_str_mv AT milonemichaelc engineeringenhancedcartcellsforimprovedcancertherapy
AT xujie engineeringenhancedcartcellsforimprovedcancertherapy
AT chensaijuan engineeringenhancedcartcellsforimprovedcancertherapy
AT collinsmckensiea engineeringenhancedcartcellsforimprovedcancertherapy
AT zhoujiafeng engineeringenhancedcartcellsforimprovedcancertherapy
AT powelldanielj engineeringenhancedcartcellsforimprovedcancertherapy
AT melenhorstjjoseph engineeringenhancedcartcellsforimprovedcancertherapy

Ejemplares similares